MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2337/dc22-1297

Медицинская библиотека · Diabetes care · 2023

CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study.

Wilson Darrell M, Pietropaolo Susan L, Acevedo-Calado Maria, Huang Shuai, Anyaiwe Destiny, Scheinker David, Steck Andrea K, Vasudevan Madhuri M, McKay Siripoom V, Sherr Jennifer L, Herold Kevan C, Dunne Jessica L, Greenbaum Carla J, Lord Sandra M, Haller Michael J, Schatz Desmond A, Atkinson Mark A, Nelson Patrick W, Pietropaolo Massimo, Type 1 Diabetes TrialNet Study Group

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

Continuous glucose monitoring (CGM) parameters may identify individuals at risk for progression to overt type 1 diabetes. We aimed to determine whether CGM metrics provide additional insights into progression to clinical stage 3 type 1 diabetes.

RESEARCH DESIGN AND

METHODS

One hundred five relatives of individuals in type 1 diabetes probands (median age 16.8 years; 89% non-Hispanic White; 43.8% female) from the TrialNet Pathway to Prevention study underwent 7-day CGM assessments and oral glucose tolerance tests (OGTTs) at 6-month intervals. The baseline data are reported here. Three groups were evaluated: individuals with 1) stage 2 type 1 diabetes (n = 42) with two or more diabetes-related autoantibodies and abnormal OGTT; 2) stage 1 type 1 diabetes (n = 53) with two or more diabetes-related autoantibodies and normal OGTT; and 3) negative test for all diabetes-related autoantibodies and normal OGTT (n = 10).

RESULTS

Multiple CGM metrics were associated with progression to stage 3 type 1 diabetes. Specifically, spending ≥5% time with glucose levels ≥140 mg/dL (P = 0.01), ≥8% time with glucose levels ≥140 mg/dL (P = 0.02), ≥5% time with glucose levels ≥160 mg/dL (P = 0.0001), and ≥8% time with glucose levels ≥160 mg/dL (P = 0.02) were all associated with progression to stage 3 disease. Stage 2 participants and those who progressed to stage 3 also exhibited higher mean daytime glucose values; spent more time with glucose values over 120, 140, and 160 mg/dL; and had greater variability.

CONCLUSIONS

CGM could aid in the identification of individuals, including those with a normal OGTT, who are likely to rapidly progress to stage 3 type 1 diabetes.

Для цитирования: Wilson Darrell M, Pietropaolo Susan L, Acevedo-Calado Maria, Huang Shuai, Anyaiwe Destiny, Scheinker David, Steck Andrea K, Vasudevan Madhuri M, McKay Siripoom V, Sherr Jennifer L, Herold Kevan C, Dunne Jessica L, Greenbaum Carla J, Lord Sandra M, Haller Michael J, Schatz Desmond A, Atkinson Mark A, Nelson Patrick W, Pietropaolo Massimo, Type 1 Diabetes TrialNet Study Group. CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study.. Diabetes care. 2023. DOI: 10.2337/dc22-1297.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.